Lutropin alfa
Luveris, Pergoveris (lutropin alfa) is a protein pharmaceutical. Lutropin alfa was first approved as Luveris on 2000-11-29. It is used to treat female infertility in the USA. It has been approved in Europe to treat female infertility and ovulation induction. The pharmaceutical is active against lutropin-choriogonadotropic hormone receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| therapeutics | D013812 |
| investigative techniques | D008919 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
287 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | — | C61 | 8 | 38 | 29 | 3 | 14 | 87 |
| Infertility | D007246 | EFO_0000545 | — | 7 | 10 | 9 | 17 | 24 | 65 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 4 | 15 | 11 | 1 | 6 | 35 |
| Female infertility | D007247 | EFO_0008560 | N97 | 4 | 1 | 1 | 5 | 4 | 15 |
| Hypogonadism | D007006 | — | E23.0 | 1 | 2 | 1 | 4 | 2 | 10 |
| Fertilization in vitro | D005307 | — | — | — | — | — | 4 | 1 | 5 |
| Male infertility | D007248 | EFO_0004248 | N46 | — | — | — | 1 | 2 | 3 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | 1 | 2 | 3 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | 1 | 1 | 2 |
| Hyperprolactinemia | D006966 | — | E22.1 | — | — | — | 1 | 1 | 2 |
Show 16 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | D000230 | — | — | 1 | 7 | 3 | — | — | 10 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | 2 | 8 | — | — | 10 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | 3 | 5 | — | 1 | 9 |
| Ovulation induction | D010062 | — | — | — | 4 | 2 | — | — | 6 |
| Neoplasms | D009369 | — | C80 | 1 | 2 | 1 | — | 1 | 5 |
| Recurrence | D012008 | — | — | — | 1 | 2 | — | 1 | 4 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | 2 | 2 | 1 | — | — | 3 |
| Precocious puberty | D011629 | — | E22.8 | — | 1 | 2 | — | — | 3 |
| Endometriosis | D004715 | EFO_0001065 | N80 | 1 | — | 1 | — | — | 2 |
| Assisted reproductive techniques | D027724 | — | — | — | — | 2 | — | — | 2 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | 2 | 2 | — | — | 1 | 4 |
| Pituitary diseases | D010900 | — | E23.7 | — | 1 | — | — | 3 | 4 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 2 | — | — | 1 | 3 |
| Contraception | D003267 | — | — | 1 | 1 | — | — | 1 | 3 |
| Carcinoma | D002277 | — | C80.0 | 1 | 3 | — | — | — | 3 |
| Male breast neoplasms | D018567 | — | — | 1 | 2 | — | — | — | 2 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | 1 | — | — | 1 | 2 |
| Premature menopause | D008594 | — | E28.31 | 1 | 1 | — | — | 1 | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | 2 | — | — | — | 2 |
| Growth disorders | D006130 | — | — | — | 1 | — | — | 1 | 2 |
Show 13 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 3 | — | — | — | 6 | 9 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 5 | — | — | — | 4 | 9 |
| Hyperandrogenism | D017588 | — | — | 4 | — | — | — | 1 | 5 |
| Puberty | D011627 | EFO_0001382 | — | 4 | — | — | — | — | 4 |
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | 1 | 3 |
| Sleep deprivation | D012892 | — | F51.12 | 2 | — | — | — | — | 2 |
| Hemophilia a | D006467 | EFO_0007267 | D66 | 1 | — | — | — | — | 1 |
| Atrophy | D001284 | — | — | 1 | — | — | — | — | 1 |
| Gynatresia | D006175 | EFO_1001335 | N85.6 | 1 | — | — | — | — | 1 |
| Pregnancy rate | D018873 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ovarian hyperstimulation syndrome | D016471 | — | — | — | — | — | — | 3 | 3 |
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 3 | 3 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | — | — | — | — | 2 | 2 |
| Menstrual cycle | D008597 | — | — | — | — | — | — | 2 | 2 |
| Preimplantation diagnosis | D019836 | — | — | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | — | — | — | 1 | 1 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | — | — | — | 1 | 1 |
| Localized scleroderma | D012594 | EFO_1001361 | L94.0 | — | — | — | — | 1 | 1 |
| Diffuse scleroderma | D045743 | EFO_0000404 | — | — | — | — | — | 1 | 1 |
Show 52 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lutropin alfa |
| INN | lutropin alfa |
| Description | Lutropin beta chain precursor (Luteinizing hormone beta subunit) (LSH-beta) |
| Classification | Protein |
| Drug class | tricyclic compounds; atropine derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201419 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 3JGY52XJNA (ChemIDplus, GSRS) |
Target
Agency Approved
LHCGR
LHCGR
Organism
Homo sapiens
Gene name
LHCGR
Gene synonyms
LCGR, LGR2, LHRHR
NCBI Gene ID
Protein name
lutropin-choriogonadotropic hormone receptor
Protein synonyms
hypergonadotropic hypogonadism, LHR, LSH-R, Luteinizing hormone receptor, lutropin/choriogonadotropin receptor
Uniprot ID
Mouse ortholog
Lhcgr (16867)
lutropin-choriogonadotropic hormone receptor (P30730)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Lutropin alfa
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,333 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
532 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use